The inhibition levels of anti-α-synuclein NAbs by simultaneous presence of 100 nM β- and γ-synuclein monomers were decreased in comparison to the previous approach in normal controls and PD patients (approximately 40–45%), but still significantly higher than in MSA patients (Fig. 10h). This evidence concerns the gene SNCA and multiple system atrophy.